NaShenMD

Endocrinology • Thousand Oaks, CA

Diabetes, Lipid Metabolism, Obesity, Thyroid

Assistant Clinical Professor David Geffen School of Medicine at UCLA

Join to view full profile

Dr. Shen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shen's full profile

Already have an account?

Office
100 Moody Court
Suite 200
Thousand Oaks, CA 91360
Phone+1 310-319-3475

Fax+1 310-319-3475
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2014
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2009 - 2012
University of Maryland School of MedicineClass of 2009

Certifications & Licensure

CA State Medical License 2011 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Obesity Medicine Obesity Medicine

Publications & Presentations

PubMed

Program for Reducing Obesity (PRO): An institutional review of an insurance-based weight loss program utilizing shared medical appointments.
Jeffrey Wei, Lei Lei, Albert Shieh, Deepashree Gupta, Susan Ahern, Na Shen> ;Obesity Science & Practice. 2022 Jun 1
6 citations
Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules.
Max A. Schumm, Dalena T Nguyen, Jiyoon Kim, Chi-Hong Tseng, Amy Y Chow, Na Shen, Masha J. Livhits> ;Annals of Surgical Oncology. 2021 Jul 22
1 citations
ASO Visual Abstract: Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules.
Max A. Schumm, Dalena T Nguyen, Jiyoon Kim, Chi-Hong Tseng, Amy Y Chow, Na Shen, Masha J. Livhits> ;Annals of Surgical Oncology. 2021 Jul 22
61 citations
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy.
Rong Deng, Na Shen, Yang Yang, Hongliang Yu, Shuping Xu, Ying-Wei Yang, Shujun Liu, Kamel Meguellati, Fei Yan> ;Biomaterials. 2018 Jun 1
10 citations
HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia
Na Shen, Fei Yan, Jiuxia Pang, Zhe Gao, Aref Al-Kali, Christy L. Haynes, Mark R. Litzow, Shujun Liu> ;ACS Applied Materials & Interfaces. 2018 Apr 10
18 citations
A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.
Fei Yan, Na Shen, Jiuxia Pang, Na Zhao, B. Deng, Bing Li, Y. Yang, Ping Yang, Julian R. Molina, Shujun Liu> ;Oncogene. 2017 Sep 4
36 citations
A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target
Fei Yan, Na Shen, Jiuxia Pang, Na Zhao, Yuwen Zhang, Ann M. Bode, Aref Al-Kali, Mark R. Litzow, Bing Li, Shujun Liu> ;Leukemia. 2018 Apr 1
24 citations
Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemia
Na Shen, Fei Yan, Jiuxia Pang, Na Zhao, Naseema Gangat, Lai-Chu Wu, Ann M. Bode, Aref Al-Kali, Mark R. Litzow, Shujun Liu> ;Clinical Cancer Research. 2017 Oct 15
60 citations
Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells
Fei Yan, Na Shen, Jiuxia Pang, Yuwen Zhang, Enyu Rao, Ann M. Bode, Aref Al-Kali, Dong-Er Zhang, Mark R. Litzow, Bing Li, Shujun Liu> ;Leukemia. 2017 Jun 1
37 citations
Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells.
Jiuxia Pang, Na Shen, Fei Yan, Na Zhao, Liping Dou, Lai-Chu Wu, Christopher L. Seiler, Li Yu, Ke Yang, Veronika Bachanova, Eric Weaver, Natalia Y. Tretyakova, Shujun Liu> ;Oncotarget. 2017 Mar 21
15 citations
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis
Xiaojuan Yang, Jiuxia Pang, Na Shen, Fei Yan, Lai-Chu Wu, Aref Al-Kali, Mark R. Litzow, Yong Peng, Robert J. Lee, Shujun Liu> ;Oncotarget. 2016 Apr 22
56 citations
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation
Xiao-Ning Gao, Fei Yan, Ji Lin, Li Gao, Xiao-Lin Lu, S. C. Wei, Na Shen, Jiuxia Pang, Qiaoyang Ning, Y. Komeno, Ailing Deng, Yihan Xu, Jinlong Shi, Yonghui Li, Dong-Er...> ;Leukemia. 2015 Aug 7
24 citations
The DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT cooperatively promote resistance to 5-aza-2′-deoxycytidine (decitabine) and midostaurin (PKC412) in lun...
Fei Yan, Na Shen, Jiuxia Pang, Julian R. Molina, Ping Yang, Shujun Liu> ;The Journal of Biological Chemistry. 2015 Jul 24
32 citations
Autologous islet transplantation with remote islet isolation after pancreas resection for chronic pancreatitis
Denise S. Tai, Na Shen, Gregory L. Szot, Andrew M. Posselt, Nicholas J. Feduska, Andrew Habashy, Barbara M. Clerkin, Erin Core, Ronald W. Busuttil, O. Joe Hines, Howar...> ;JAMA Surgery. 2015 Feb 1
64 citations
Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation.
Fei Yan, Na Shen, Jiuxia Pang, D. Xie, B. Deng, Julian R. Molina, Ping Yang, Shujun Liu> ;Cell Death & Disease. 2014 Jan 1
43 citations
A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis
Na Shen, Fei Yan, Jiuxia Pang, Lai-Chu Wu, Aref Al-Kali, Mark R. Litzow, Shujun Liu> ;Oncotarget. 2014 Jun 26
131 citations
CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling
Xiaolin Wan, Na Shen, Arnulfo Mendoza, Chand Khanna, Lee J. Helman> ;Neoplasia. 2006 May 1
Join now to see all

Hospital Affiliations

Ronald Reagan UCLA Medical CenterLos Angeles, California
Los Robles Health SystemThousand Oaks, California